NEW YORK--(EON: Enhanced Online News)--Rosen Law Firm, a global investor rights law firm, announces it is
investigating potential securities claims on behalf of shareholders of
Lion Biotechnologies, Inc. (NASDAQ:LBIO) resulting from allegations that
Lion may have issued materially misleading business information to the
investing public.

On April 10, 2017, the U.S. Securities and Exchange Commission found
that between “September 2013 to March 2014, Lion, through its former
Chief Executive Officer, Manish Singh, engaged in a scheme to mislead
investors by commissioning over 10 internet publications and 20 widely
distributed emails promoting Lion to potential investors that purported
to be independent from the company when, in fact, they were paid
promotions. Singh engaged Lidingo Holdings, a stock promotion firm, to
pay writers to publish articles about Lion on investment websites as
well as to coordinate the distribution of articles to thousands of
electronic mailboxes. Singh actively participated in Lidingo’s
promotional work for Lion and understood that Lidingo was using writers
who would not disclose that Lion was indirectly compensating them for
their publications.” On this news, shares of Lion fell $0.20 per share
or 3.05% to close at $6.35 per share on April 10, 2017.

Rosen Law Firm is preparing a class action lawsuit to recover losses
suffered by Lion investors. If you purchased shares of Lion on or before
April 10, 2017, please visit the firm’s website at http://www.rosenlegal.com/cases-1100.html
for more information. You may also contact Phillip Kim or Kevin Chan of
Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com
or kchan@rosenlegal.com.